Beijing Tong Ren Tang Chinese Medicine Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Wang Chi

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	2.3yrs

Recente managementupdates

Recent updates

CEO

Wang Chi (49 yo)

less than a year

Tenure

Mr. Wang Chi is Executive Director and Chief Executive Officer of Beijing Tong Ren Tang Chinese Medicine Company Limited from May 10, 2024. Mr. Chi has experience in Medical and Pharmaceutical industry. Mr...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Hai Ou Gu	Executive Chairman of the Board	less than a year	geen gegevens	geen gegevens
Fei Chen	Executive Director & Executive Deputy GM	less than a year	HK$975.00k	0.0073% HK$ 502.2k
Wang Chi	CEO & Executive Director	less than a year	geen gegevens	geen gegevens
Fung Yi Tsang	CFO & Company Secretary	4.5yrs	geen gegevens	geen gegevens
Zheng Guo Shen	Deputy GM & General Counsel	no data	geen gegevens	geen gegevens

0.7yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 3613 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Hai Ou Gu	Executive Chairman of the Board	less than a year	geen gegevens	geen gegevens
Fei Chen	Executive Director & Executive Deputy GM	4.7yrs	HK$975.00k	0.0073% HK$ 502.2k
Wang Chi	CEO & Executive Director	less than a year	geen gegevens	geen gegevens
Yok-Sing Tsang	Independent Non-Executive Director	7.2yrs	HK$288.00k	geen gegevens
Ngai Chi Chan	Independent Non-Executive Director	11.6yrs	HK$288.00k	geen gegevens
Li Feng	Non-Executive Director	2.3yrs	geen gegevens	geen gegevens
Hong Xi Xu	Independent Non-Executive Director	1.7yrs	HK$240.00k	geen gegevens

2.3yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 3613 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.3 jaar), wat duidt op een nieuw bestuur.

Beijing Tong Ren Tang Chinese Medicine Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Wang Chi as an Executive Director and a Member of the Competition Executive Committee

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces CEO Changes

Beijing Tong Ren Tang Chinese Medicine Company Limited, Annual General Meeting, May 31, 2024

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Gu Hai Ou as Executive Director, Chairman of Board and Authorised Representative

Recent updates

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 22%

First half 2024 earnings released: EPS: HK$0.26 (vs HK$0.32 in 1H 2023)

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2024 Results on Aug 30, 2024

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended December 31, 2023

Now 22% overvalued after recent price rise

Upcoming dividend of HK$0.33 per share

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Wang Chi as an Executive Director and a Member of the Competition Executive Committee

Now 21% overvalued after recent price rise

Full year 2023 earnings released: EPS: HK$0.65 (vs HK$0.77 in FY 2022)

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces CEO Changes

Beijing Tong Ren Tang Chinese Medicine Company Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: EPS: HK$0.65 (vs HK$0.77 in FY 2022)

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on June 17,2024

New minor risk - Financial data availability

Investor sentiment deteriorates as stock falls 17%

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2023 Results on Mar 31, 2024

Now 21% undervalued after recent price drop

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Gu Hai Ou as Executive Director, Chairman of Board and Authorised Representative

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2023 Results on Oct 31, 2023

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Resignation of Lin Man as Executive Director, Chief Operating Officer, Member of Competition Executive Committee

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Retirement of Ding Yong Ling as Executive Director and Chairman of the Board

First half 2023 earnings released: EPS: HK$0.32 (vs HK$0.26 in 1H 2022)

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2023 Results on Aug 10, 2023

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.33 per share at 2.1% yield

Full year 2022 earnings released: EPS: HK$0.77 (vs HK$0.73 in FY 2021)

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2022 Results on Oct 31, 2022

Upcoming dividend of HK$0.25 per share

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Special Interim Dividend, Payable on 21 October 2022

Less than half of directors are independent

COO & Executive Director recently bought HK$183k worth of stock

First half 2022 earnings released

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Feng Li as Executive Director

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2022 Results on Aug 12, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.28 per share

Full year 2021 earnings released: EPS: HK$0.73 (vs HK$0.65 in FY 2020)

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Final Dividend for the Year Ended 31 December 2021

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2021 Results on Mar 07, 2022

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$178k worth of stock

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended 31 December 2020

Investor sentiment improved over the past week

Upcoming dividend of HK$0.24 per share

Full year 2020 earnings released: EPS HK$0.65 (vs HK$0.66 in FY 2019)

Beijing Tong Ren Tang Chinese Medicine Company Limited, Annual General Meeting, May 28, 2021

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Appointment of Chen Fei as Executive Director

CEO & Executive Director Huan Ping Zhang has left the company

Full year 2020 earnings released: EPS HK$0.65 (vs HK$0.66 in FY 2019)

Revenue beats expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2020 Results on Mar 11, 2021

Investor sentiment improved over the past week

New 90-day high: HK$9.58

Beijing Tong Ren Tang Chinese Medicine Company Limited (SEHK:3613) entered into the Sale and Purchase Agreement to acquire 40% stake in Beijing Tong Ren Tang WM Dianorm Biotech Co., Limited from WM Dianorm Biotech Co., Limited for RMB 33.1 million.

New 90-day high: HK$9.25

New 90-day low: HK$8.04

New 90-day low: HK$8.20

Chairman recently bought HK$257k worth of stock

New 90-day low - HK$8.66

First half earnings released

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2020 Results on Aug 13, 2020

New 90-day low - HK$9.28

CEO